{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T04:52:32Z","timestamp":1778043152105,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T00:00:00Z","timestamp":1678147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T00:00:00Z","timestamp":1678147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s00774-023-01408-z","type":"journal-article","created":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T03:02:52Z","timestamp":1678158172000},"page":"301-306","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Differences between zoledronic acid and denosumab for breast cancer treatment"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3450-4533","authenticated-orcid":false,"given":"Takashi","family":"Ishikawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,7]]},"reference":[{"key":"1408_CR1","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S0140-6736(15)60908-4","volume":"386","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2015","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG) (2015) Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet 386:1353\u20131361","journal-title":"Lancet"},{"key":"1408_CR2","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.bone.2015.06.002","volume":"79","author":"S Pagani","year":"2015","unstructured":"Pagani S, Fini M, Giavaresi G, Salamanna F, Borsari V (2015) The active role of osteoporosis in the interaction between osteoblasts and bone metastases. Bone 79:176\u2013182","journal-title":"Bone"},{"key":"1408_CR3","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.breast.2018.06.013","volume":"41","author":"F Salamanna","year":"2018","unstructured":"Salamanna F, Borsari V, Contartese D, Nicoli Aldini N, Fini M (2018) Link between estrogen deficiency osteoporosis and susceptibility to bone metastases: a way towards precision medicine in cancer patients. Breast 41:42\u201350","journal-title":"Breast"},{"key":"1408_CR4","doi-asserted-by":"publisher","first-page":"2922","DOI":"10.1158\/1078-0432.CCR-13-1246","volume":"20","author":"PD Ottewell","year":"2014","unstructured":"Ottewell PD, Wang N, Brown HK, Reeves KJ, Fowles CA, Croucher PI, Eaton CL, Holen I (2014) Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo. Clin Cancer Res 20:2922\u20132932","journal-title":"Clin Cancer Res"},{"key":"1408_CR5","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/978-1-4419-9129-4_10","volume":"118","author":"T Yoneda","year":"2004","unstructured":"Yoneda T, Hashimoto N, Hiraga T (2004) Bisphosphonate actions on bone and visceral metastases. Cancer Treat Res 118:213\u2013229","journal-title":"Cancer Treat Res"},{"key":"1408_CR6","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1023\/A:1019905111666","volume":"75","author":"T Michigami","year":"2002","unstructured":"Michigami T, Hiraga T, Williams PJ, Niewolna M, Nishimura R, Mundy GR, Yoneda T (2002) The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs. Breast Cancer Res Treat 75:249\u2013258","journal-title":"Breast Cancer Res Treat"},{"key":"1408_CR7","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","volume":"21","author":"LS Rosen","year":"2003","unstructured":"Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, de Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman JJ (2003) Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial\u2013the zoledronic acid lung cancer and other solid tumors study group. J Clin Oncol 21:3150\u20133157","journal-title":"J Clin Oncol"},{"key":"1408_CR8","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","volume":"94","author":"F Saad","year":"2002","unstructured":"Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B, Zoledronic Acid Prostate Cancer Study Group (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458\u20131468","journal-title":"J Natl Cancer Inst"},{"key":"1408_CR9","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","volume":"23","author":"N Kohno","year":"2005","unstructured":"Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y, Watanabe T, Goessl C, Ohashi Y, Takashima S (2005) Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 23:3314\u20133321","journal-title":"J Clin Oncol"},{"key":"1408_CR10","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1056\/NEJMoa0806285","volume":"360","author":"M Gnant","year":"2009","unstructured":"Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, P\u00f6stlberger S et al (2009) Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360:679\u2013691","journal-title":"N Engl J Med"},{"key":"1408_CR11","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1093\/annonc\/mdu544","volume":"26","author":"M Gnant","year":"2015","unstructured":"Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Knauer M et al (2015) Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian breast and colorectal cancer study group trial 12. Ann Oncol 26:313\u2013320","journal-title":"Ann Oncol"},{"key":"1408_CR12","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/S1470-2045(14)70302-X","volume":"15","author":"R Coleman","year":"2014","unstructured":"Coleman R, Cameron D, Dodwell D, Bell R, Wilson C, Rathbone E, Keane M, Gil M, Burkinshaw R, Grieve R, Barrett-Lee P, Ritchie D, Liversedge V, Hinsley S, Marshall H (2014) Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01\/04) randomised open-label phase 3 trial. Lancet Oncol 15:997\u20131006","journal-title":"Lancet Oncol"},{"key":"1408_CR13","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S1470-2045(10)70054-1","volume":"11","author":"R Aft","year":"2010","unstructured":"Aft R, Naughton M, Trinkaus K, Watson M, Ylagan L, Chavez-MacGregor M (2010) Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol 11:421\u2013428","journal-title":"Lancet Oncol"},{"key":"1408_CR14","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1038\/sj.bjc.6605604","volume":"102","author":"RE Coleman","year":"2010","unstructured":"Coleman RE, Winter MC, Cameron D, Bell R, Dodwell D, Keane MM, Gil M, Ritchie D, Passos-Coelho JL, Wheatley D, Burkinshaw R, Marshall SJ, Thorpe H (2010) The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer 102:1099\u20131105","journal-title":"Br J Cancer"},{"key":"1408_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0143643","volume":"10","author":"Y Hasegawa","year":"2015","unstructured":"Hasegawa Y, Tanino H, Horiguchi J, Miura D, Ishikawa T, Hayashi M, Takao S, Kim SJ, Yamagami K, Miyashita M, Konishi M, Shigeoka Y, Suzuki M, Taguchi T, Kubota T, Akazawa K, Kohno N (2015) Randomized controlled trial of zoledronic acid plus chemotherapy versus chemotherapy alone as neoadjuvant treatment of HER2-negative primary breast cancer (JONIE Study). PLoS ONE 10:e0143643","journal-title":"PLoS ONE"},{"key":"1408_CR16","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1093\/annonc\/mdu102","volume":"25","author":"A Charehbili","year":"2014","unstructured":"Charehbili A, van de Ven S, Smit VTHB, Meershoek-Klein-Kranenbarg E, Hamdy NAT et al (2014) Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2 negative stage II\/III breast cancer: the NEOZOTAC trial (BOOG 2010\u201301). Ann Oncol 25:998\u20131004","journal-title":"Ann Oncol"},{"key":"1408_CR17","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejca.2015.10.011","volume":"54","author":"JR Kroep","year":"2016","unstructured":"Kroep JR, Charehbili A, Coleman RE, Aft RL, Hasegawa Y, Winter MC, Weilbaecher K, Akazawa K, Hinsley S, Putter H, Liefers GJ, Nortier JWR, Kohno N (2016) Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: a meta-analysis of randomised trials. Eur J Cancer 54:57\u201363","journal-title":"Eur J Cancer"},{"key":"1408_CR18","unstructured":"NCCN guidelines Version 3. 2022 Invasive breast cancer"},{"key":"1408_CR19","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","volume":"28","author":"AT Stopeck","year":"2010","unstructured":"Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28:5132\u20135139","journal-title":"J Clin Oncol"},{"key":"1408_CR20","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","volume":"386","author":"M Gnant","year":"2015","unstructured":"Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R et al (2015) Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 386:433\u2013443","journal-title":"Lancet"},{"key":"1408_CR21","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S1470-2045(19)30687-4","volume":"21","author":"R Coleman","year":"2020","unstructured":"Coleman R, Finkelstein DM, Barrios C, Martin M, Iwata H, Hegg R, Glaspy J, Peria\u00f1ez AM, Tonkin K, Deleu I, Sohn J, Crown J, Delaloge S, Dai T, Zhou Y, Jandial D, Chan A (2020) Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 21:60\u201372","journal-title":"Lancet Oncol"},{"key":"1408_CR22","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1111\/febs.13645","volume":"283","author":"E Gonz\u00e1lez-Su\u00e1rez","year":"2016","unstructured":"Gonz\u00e1lez-Su\u00e1rez E, Sanz-Moreno A (2016) RANK as a therapeutic target in cancer. FEBS J 283:2018\u20132033","journal-title":"FEBS J"},{"key":"1408_CR23","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s10549-017-4233-5","volume":"164","author":"ME Reyes","year":"2017","unstructured":"Reyes ME, Fujii T, Branstetter D, Krishnamurthy S, Masuda H, Wang X, Reuben JM, Woodward WA, Edwards BJ, Hortobagyi GN, Tripathy D, Dougall WC, Eckhardt BL, Ueno NT (2017) Poor prognosis of patients with triple-negative breast cancer can be stratified by RANK and RANKL dual expression. Breast Cancer Res Treat 164:57\u201367","journal-title":"Breast Cancer Res Treat"},{"key":"1408_CR24","doi-asserted-by":"publisher","first-page":"S303","DOI":"10.1016\/j.annonc.2020.08.290","volume":"31","author":"T Link","year":"2020","unstructured":"Link T, Blohmer J, Just M, Untch M, St\u00f6tzer O, Fasching PA, Schneeweiss A, Wimberger P, Seiler S, Huober J, Schmitt WD, Jackisch C, Rhiem KE, Hanusch C, Denkert C, Sinn BV, Engels K, Nekljudova V, Loibl S (2020) GeparX: denosumab as add-on to different regimen of nab-paclitaxel-anthracycline based neoadjuvant chemotherapy in early breast cancer: subgroup analyses by RANK expression and HR status. Ann Oncol 31:S303\u2013S339","journal-title":"Ann Oncol"},{"key":"1408_CR25","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/nm.4118","volume":"22","author":"E Nolan","year":"2016","unstructured":"Nolan E, Vaillant F, Branstetter D, Pal B, Giner G, Whitehead L, Lok SW, Mann GB, Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), Rohrbach K, Huang LY, Soriano R, Smyth GK, Dougall WC, Visvader JE, Lindeman GJ (2016) RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers. Nat Med 22:933\u2013939","journal-title":"Nat Med"},{"key":"1408_CR26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s10549-016-4029-z","volume":"161","author":"J Kotsopoulos","year":"2017","unstructured":"Kotsopoulos J, Singer C, Narod SA (2017) Can we prevent BRCA1-associated breast cancer by RANKL inhibition? Breast Cancer Res Treat 161:11\u201316","journal-title":"Breast Cancer Res Treat"},{"key":"1408_CR27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS10616","author":"N Bhulani","year":"2022","unstructured":"Bhulani N, Wood M, Tsai J, Bedrosian I, Hopkins JO, Brunet J, Michaelson-Cohen R, Schmutzler RK, Evans GD, Gnant M, Fesl C, Mystek A, Lindeman GJ, Singer CF, Garber JE (2022) A phase 3 study to determine the breast cancer risk reducing effect of denosumab in women carrying a germline BRCA1 mutation (BRCA-P study). J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.TPS10616","journal-title":"J Clin Oncol"},{"key":"1408_CR28","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s00774-016-0810-7","volume":"35","author":"T Yoneda","year":"2017","unstructured":"Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S, Taguchi A, Nagata T, Urade M, Shibahara T, Toyosawa S (2017) Antiresorptive anti-agent osteonecrosis of the jaw: position paper 2017 ofthe Japanese allied committee on osteonecrosis of the jaw. J Bone Miner Metab 35:6\u201319","journal-title":"J Bone Miner Metab"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-023-01408-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00774-023-01408-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-023-01408-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T04:25:05Z","timestamp":1685334305000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00774-023-01408-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,7]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["1408"],"URL":"https:\/\/doi.org\/10.1007\/s00774-023-01408-z","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,7]]},"assertion":[{"value":"30 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}